DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Subtle Medical closes RSNA with CE mark and FDA clearance of PET AI solution Speeds up scans by factor of four, enhanced image quality

Siemens unveils syngo Virtual Cockpit software for CT, MR and PET at RSNA Offers remote expert technicians when needed

Total-body PET scanner produces landmark human images First ever simultaneously captured 3-D image of the entire human body

South African NTP Radioisotopes facility reopens following year-long closure Will help alleviate worldwide shortages of Mo-99 and other isotopes

TeamBest companies to acquire ABT Molecular Imaging, launch Best ABT Bringing greater expertise to smaller cyclotron technology

Dr. Bernhard Sixt Edinburgh Molecular Imaging appoints as new Chief Executive Officer

Missouri reactor becomes sole US domestic source of I-131 A vital radioisotope in the fight against thyroid cancer and hyperthyroidism

Cardinal Health to distribute IRE ELiT's 68-Ga generators Aiming to alleviate access shortages with Galli Eo generators

Zionexa partners with Columbia PET Center on development of EstroTep Identifies estrogen receptor status to diagnose metastatic breast cancer

Canada to build medical isotope research and development center Will act as a regional source for isotopes, including Tc-99m

PET/CT study aims to reduce pediatric brain cancer deaths from 90 percent

by John W. Mitchell , Senior Correspondent
A group of Dutch researchers, weary of the high mortality rate associated with pediatric brainstem cancer, have gained insight into drug delivery using PET/CT imaging.

Through their work, they were able to determine the likelihood of the anti-cancer drug bevacizumab (Avastin) reaching the tumor.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



The findings will help better predict treatment response in children with diffuse intrinsic pontine glioma (DIPG), a form of brainstem cancer.

"Meeting families whose child suffers from DIPG is one of the hardest and most challenging things in our daily routine, because despite decades of research the survival of patients with DIPG still does not exceed 10 percent at two years after diagnosis," Sophie E.M. Veldhuijzen van Zanten, M.D. and Ph.D. candidate in pediatric oncology at the VU University Medical Center in Amsterdam told HCB News. "Most children die within nine months from experiencing the first symptoms."

This led to a hypothesis that there is a drug delivery problem across the blood-brain-barrier in DIPG. In short, the team suspected that drugs might not reach the tumor properly. This hypothesis, however, had never before been substantiated by medical experiments in humans.

The study findings, which were just published in the Journal of Nuclear Medicine, show the inability for drugs to reach the tumor appropriately in children with DIPG. They demonstrated this by measuring the tumor uptake of zirconium-89 (Zr-89)-labeled bevacizumab with PET.

Their findings suggest that drug delivery between children with DIPG varies. Ideally, only those patients who show drug uptake in their tumor should be treated. In addition, they evaluated the safety of the procedure and determined the optimal timing for imaging.

These findings may help the DIPG research field that, so far, has not yielded much good news. The high mortality rate for children with DIPG contrasts, for example, with children diagnosed with another common childhood cancer, leukemia. Since the 1950's, survival rates for leukemia have increased to about 85 percent, according to Marc H.A. Jansen, M.D., Ph.D., one of the other research team members.

“Our results support the development of new routes to reach the tumor in DIPG, such as administering drugs directly to the tumor by convection-enhanced delivery,” he said. "In addition, by showing that the procedures are feasible in children, we paved the way to extend the field of molecular drug imaging in children. This technique may be helpful to explore the potential of any therapeutic agent in any type of childhood solid cancer," he said.

According to Veldhuijzen van Zanten and Jansen, children with cancer are particularly likely to benefit from molecular drug imaging. Since drugs without proven therapeutic effect may cause lifelong side effects, the research also helps to potentially reduce harm to children.

Only seven children participated in the pilot study. The research team is now expanding the study to other brain tumors in children, and is planning to study other antibodies and inhibitors as well.

"Our study is the first molecular drug imaging study ever performed in children, and the first to show that indeed there is considerable heterogeneity in drug uptake of bevacizumab (Avastin) among DIPG patients, and even within DIPG tumors," concluded Veldhuijzen van Zanten.

Other members of the research team from the pediatric oncology/hematology and radiology and nuclear medicine departments at VUUMC included: Veldhuijzen van Zanten, M.D.; Guus A. van Dongen, M.D. and Gert-Jan L. Kaspers, M.D.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED